9 Meters Biopharma Overview
- Founded
-
2012
- Status
-
Public
- Employees
-
21
- Stock Symbol
-
NMTR
- Investments
-
4
- Share Price
-
$1.32
- (As of Monday Closing)
9 Meters Biopharma General Information
Description
9 Meters Biopharma Inc is a clinical-stage biopharmaceutical company focused on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. Its products include NM-002, Larazotide, NM-003 and others.
Contact Information
Website
www.9meters.com
Formerly Known As
Innovate Biopharmaceuticals, Inc., Innovate Biopharmaceuticals Incorporation, 9 Meters Biopharma, Incorporated, Innovate Biopharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Stock Exchange
NAS
Primary Office
- 4509 Creedmoor Road
- Suite 201
- Raleigh, NC 27612
- United States
+1 (919) 000-0000
9 Meters Biopharma Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.32 | $1.38 | $1.00 - $13.20 | $19.8M | 14.3M | 112K | -$3.18 |
9 Meters Biopharma Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 26,394 | 196,794 | 163,779 | 15,059 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (40,754) | (36,747) | (57,451) | (25,387) |
| Net Income | (41,391) | (36,779) | (61,496) | (27,049) |
| Total Assets | 42,135 | 50,174 | 39,159 | 5,297 |
| Total Debt | 18,518 | 168 | 231 | 3,227 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
9 Meters Biopharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
9 Meters Biopharma Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
9 Meters Biopharma Inc is a clinical-stage biopharmaceutical company focused on rare and unmet needs in gastroenterology
Drug Discovery
Raleigh, NC
21
As of 2021
000.00
000000 - 000
000.00
000000
smod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
0000 000000000
Boston, MA
000
As of 0000
00000
000000000
00000
000000
ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor i
0000 000000000
San Diego, CA
000
As of 0000
00000
000000000
00000
Add Comparison
9 Meters Biopharma Competitors (8)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals | Formerly VC-backed | Boston, MA | 000 | 00000 | 000000000 | 00000 |
| 000000000 00000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000000 | 00000 |
| 000 00000000000 | Venture Capital-Backed | Princeton, NJ | 00 | 0000 | 0000000000 0 | 0000 |
| 000000 00000000000 | Corporation | Plymouth Meeting, PA | 000 | 000.00 | 00000000 | 000.00 |
| 00000000 | Venture Capital-Backed | Vienna, Austria | 00.00 | 0000000000 | 00.00 |
9 Meters Biopharma Patents
9 Meters Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220265684-A1 | Compositions and methods for treating ulcerative colitis | Inactive | 24-Feb-2021 | 0000000000 | |
| EP-4135737-A1 | Larazotide derivatives comprising d-amino acids | Pending | 15-Apr-2020 | 000000000 | |
| AU-2021255955-A1 | Larazotide derivatives comprising d-amino acids | Pending | 15-Apr-2020 | 000000000 | |
| CA-3175340-A1 | Larazotide derivatives comprising d-amino acids | Pending | 15-Apr-2020 | 000000000 | |
| AU-2020333555-A1 | Larazotide formulations | Pending | 16-Aug-2019 |
9 Meters Biopharma Executive Team (13)
9 Meters Biopharma Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| John Temperato | 9 Meters Biopharma | Chief Executive Officer & Board Member | 000 0000 |
| Lorin Johnson Ph.D | Self | Board Member | 000 0000 |
| Mark Sirgo Ph.D | Self | Chairman & Board Member | 000 0000 |
| Michael Constantino | 9 Meters Biopharma | Board Member | 000 0000 |
| Michael Rice | Self | Board Member | 000 0000 |
9 Meters Biopharma Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
9 Meters Biopharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
9 Meters Biopharma Acquisitions (4)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 | 19-Jul-2021 | 0000000000 | 00000 | Drug Discovery | |
| 0000 00000000 | 06-May-2020 | 0000000000 | 00.00 | Pharmaceuticals | |
| 000 000000 | 01-May-2020 | 0000000000 | Drug Discovery | ||
| Monster Digital | 29-Jan-2018 | Merger/Acquisition | 0000 | Storage (IT) | 000000000 |
9 Meters Biopharma Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 0000 0000000000000 | Pharmaceuticals | Richmond, CA | 0000 |
9 Meters Biopharma ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
36.01 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,912
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 965
Rank
00.00
Percentile
Biotechnology
Subindustry
00 of 443
Rank
00.00
Percentile
